Spinal Muscular Atrophy Type II
9
0
3
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
11.1%
1 terminated out of 9 trials
80.0%
-6.5% vs benchmark
11%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb
Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi
Spinraza in Adult Spinal Muscular Atrophy
Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain
Body Weight Support Harness System in Spinal Muscular Atrophy
Spinal Cord Gray Matter Imaging in Spinal Muscular Atrophy
Exoskeleton Impact on the Quality of Life on Patients With Spinal Muscular Atrophy
Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.
Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III